Jane Street
AEGR

Jane Street’s Aegerion Pharmaceuticals AEGR Stock Holding History

Jane Street’s Portfolio AEGR Stock Details AEGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-14,214
Closed -$21K – 4876
2016
Q2 		$21K Buy
+14,214
New +$32.5K ﹤0.01% 3982
2013
Q3 		– Sell
-30,021
Closed -$1.9M – 3392
2013
Q2 		$1.9M Buy
+30,021
New +$1.59M 0.03% 486

Other funds holding AEGR

SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
DCM
DG Capital Management New York $326M AUM 39.67% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
JG
Jefferies Group New York $12B AUM 6.2% 1-Year Est. Return

Jane Street's AEGR Position: Q3 2016 in Review

Jane Street sold out of Aegerion Pharmaceuticals (AEGR) in Q3 2016, closing a stake of 14,214 shares — an estimated $21K sold.

Jane Street first reported a position in AEGR in Q2 2013 and held it in 2 quarters. The position peaked at $1.9M in Q2 2013. 58 funds tracked by Wall St. Rank hold AEGR as of Q3 2016.

  • Jane Street reported no remaining Aegerion Pharmaceuticals position as of Q3 2016 after selling out during the quarter.
  • Jane Street sold 14,214 Aegerion Pharmaceuticals shares in Q3 2016, an estimated $21K.
  • Jane Street first reported a position in Aegerion Pharmaceuticals in Q2 2013 and held it in 2 quarters.
  • Jane Street's Aegerion Pharmaceuticals position peaked at $1.9M in Q2 2013.
  • 58 funds tracked by Wall St. Rank held Aegerion Pharmaceuticals as of Q3 2016.

Based on Jane Street's 13F filing for Q3 2016, filed 15 Nov 2016.